JP Morgan Chase
MLYS icon

JP Morgan Chase’s Mineralys Therapeutics MLYS Stock Holding History

JP Morgan Chase’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,900
Closed -$1.1M – 7639
2025
Q3 		$1.1M Buy
+28,900
New +$625K ﹤0.01% 4514
2025
Q2 		– Sell
-41,900
Closed -$665K – 7430
2025
Q1 		$665K Buy
+41,900
New +$482K ﹤0.01% 4600

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase's MLYS Position: Q2 2026 in Review

JP Morgan Chase reduced its Mineralys Therapeutics (MLYS) stake by 4.4% in Q2 2026, selling an estimated $63.3K and leaving 49,615 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #4445.

JP Morgan Chase first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $6.97M in Q3 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • JP Morgan Chase held 49,615 shares of Mineralys Therapeutics worth $1.4M as of Q2 2026.
  • JP Morgan Chase sold 2,307 Mineralys Therapeutics shares in Q2 2026, an estimated $63.3K.
  • Mineralys Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4445 holding.
  • JP Morgan Chase first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • JP Morgan Chase's Mineralys Therapeutics position peaked at $6.97M in Q3 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.